An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Antoniotti C, Boccaccino A, Seitz R, Giordano M, Catteau A, Rossini D, Pietrantonio F, Salvatore L, McGregor K, Bergamo F, Conca V, Leonetti S, Morano F, Papiani G, Tamburini E, Bensi M, Murgioni S, Ross DT, Passardi A, Boquet I, Nielsen TJ, Galon J, Varga MG, Schweitzer BL, Cremolini C.
Antoniotti C, et al. Among authors: papiani g.
Clin Cancer Res. 2023 Jun 13;29(12):2291-2298. doi: 10.1158/1078-0432.CCR-22-3878.
Clin Cancer Res. 2023.
PMID: 37022350
Clinical Trial.